TirzepatideTales

My GLP1 Journey

[TirzepatideTales @TirzepatideTale]

🚨 Big shake-up at Novo Nordisk 🚨 The company behind some of the most popular GLP-1s just: 📉 Cut projections for 2025 ⚖️ Lost more market share to Eli Lilly 👔 Replaced long-time CEO Lars Jørgensen with Maziar “Mike” Doustdar This is huge — Novo once dominated the GLP-1 space,

[TirzepatideTales @TirzepatideTale]

From pharma shake-ups to FDA warnings and even TikTok tightening the rules — today’s GLP-1 news shows how fast things are changing. 🚨 #GLP1News #HealthUpdates #FDANews #PharmaNews #TikTokNews

[TirzepatideTales @TirzepatideTale]

🚨 GLP-1 Daily News 🚨 From lawsuits over vision loss 👁️ to the race for oral GLP-1 pills 💊, plus celebs admitting to microdosing… the headlines keep coming. Stay tuned for your quick daily breakdown of the biggest GLP-1 stories — so you know what’s hype, what’s fact, and

[TirzepatideTales @TirzepatideTale]

🚨 Big update in the GLP-1 world 🚨 I just dropped the full breakdown of the next generation of clinical trials to watch in 2025. Investors, patients, and providers — you’ll want to see this. Full story is live now on my Substack (linked in bio)! #GLP1News #ClinicalTrials

[TirzepatideTales @TirzepatideTale]

⚡ GLP-1 Daily Update (2 min) ⚡ Here’s what’s new this week: 1️⃣ Doctors warn pregnancy risks are being overlooked when patients start GLP-1 therapy ⚠️ 2️⃣ Lab studies show these medications may help curb addictive behaviors 🧠 3️⃣ Research finds many people stop treatment early

[TirzepatideTales @TirzepatideTale]

🚨 GLP-1 Daily Update 🚨 Today’s big moves: 1️⃣ Europe expands approval for oral GLP-1 therapy to include cardiovascular risk reduction 💊❤️ 2️⃣ A new U.S. bill could reshape how compounded GLP-1 medications are regulated and accessed ⚖️ From heart health to

[TirzepatideTales @TirzepatideTale]

🚨 GLP-1 News Daily 🚨 FDA cracks down on ads, a telepharmacy fined for fake meds, & Lilly/Novo racing for oral launches. Plus new research on patient outcomes 👩‍⚕️📊 Full breakdown in today’s Substack — link in bio! #GLP1 #WeightLossNews #PharmaNews #HealthUpdate #substack

[TirzepatideTales @TirzepatideTale]

🚨Daily GLP-1 news for September 18 🚨 From emotional eating to genetic testing, GLP-1 news is changing FAST 🧬💊✨ New pill options, kids’ studies, and even benefits for psoriasis 👀 Stay updated here daily. ##GLP1Update##WeightLossJourney##HealthNews##ObesityCare##DailyUpdate

[TirzepatideTales @TirzepatideTale]

🚨 Daily GLP-1 News 🚨 1️⃣ Congress drops a new bill to protect patient access to compounded meds during shortages 2️⃣ Lilly invests $5B in a new Virginia plant to boost GLP-1 production 3️⃣ Chrissy Teigen shares her personal GLP-1 journey after pregnancy loss 4️⃣ Novo Nordisk

[TirzepatideTales @TirzepatideTale]

🚨 GLP-1 Access Alert 🚨 Congress just introduced H.R. 5316 — the Drug Shortage Compounding Patient Access Act of 2025. This bill would: ⚡ Allow hospitals to compound meds in urgent cases during shortages ⚡ Redefine what counts as a “copy” so patients don’t

[TirzepatideTales @TirzepatideTale]

🚨 GLP-1 Daily News 🚨 1️⃣ Pfizer makes a $4.9B move into weight-loss drugs 2️⃣ Debate heats up: $6K/year meds vs long-term savings 3️⃣ A key semaglutide patent lapses in Canada 👀 The GLP-1 space is moving fast — here’s what it means for access, cost, and

[TirzepatideTales @TirzepatideTale]

New research from Dr. Mitch Berryman looks at what happens when GLP-1 frequency is reduced in real-world patients. 🧬 These findings highlight how personalized care and ongoing provider guidance make all the difference. 🎓 Educational content only — not medical advice.

[TirzepatideTales @TirzepatideTale]

Wanna know what’s really happening in the GLP-1 landscape? 👀 I pulled insights from ICER + Morningstar to break down what the big pharma players have in the pipeline — release dates, phases of clinical trials, and the future of this space. 🚨📊 #GLP1 #HealthNews #ClinicalTrials

[TirzepatideTales @TirzepatideTale]

New research from #ObesityWeek dives into how GLP-1s might affect muscle mass and inflammation. 🧬 Researchers from Korea, including Dr. Su Lim and Dr. Yumi Kang, discussed how GLP-1s may reduce inflammation in fat and muscle cells — improving function even when muscle size

[TirzepatideTales @TirzepatideTale]

I ended up at Obesity Week — one of the biggest research conferences on obesity and GLP-1s in the world. I swear I was just gonna read one paper… #ObesityWeek #GLP1 #Tirzepatide #ResearchGirlEra #ScienceTok

[TirzepatideTales @TirzepatideTale]

Big news in the GLP-1 world 👀 Novo Nordisk and Eli Lilly are reportedly in talks with the President about lowering GLP-1 pricing — with discussions suggesting costs could drop to around $150/month. That’s a massive step forward for affordability and access to these

[TirzepatideTales @TirzepatideTale]

I just spent a week at #ObesityWeek and here’s what really surprised me… 🧬 In almost every talk about GLP-1s, compounding wasn’t discussed at all — until the very last session, where it was framed as dangerous without presenting real data or context. I believe every patient

[TirzepatideTales @TirzepatideTale]

🚨New data alert from #ObesityWeek2025: Real-world telehealth data shows that side effects from GLP-1 medications are far less common than most people think. Within the first 2–3 months, less than 1% of patients report side effects — and even at the highest, it’s only about 10%

[TirzepatideTales @TirzepatideTale]

Using a GLP-1 med and thinking about Botox? Here’s what recent modelling research suggests about how these two treatments might interact—and what it means for your results. Disclaimer: Educational only, not medical advice. #GLP1s #BotoxEffect #CosmeticMed #HealthEducation

[TirzepatideTales @TirzepatideTale]

GLP-1 Daily News: Monday Sept. 22, 2025 🚨 GLP-1 Daily News 🚨
$PFE $LLY $NVO https://t.co/YZwmPme9Ai